Ireland
--:--IST

← All drugs

Amoxil

Amoxicillin

A first-line antibiotic for many common bacterial infections.

Generic name
Amoxicillin
Brand name
Amoxil
Route
Oral
Marketed by
GlaxoSmithKline
First FDA approval
18 Jan 1974

Where Amoxicillin is approved

All regulators →

Of the three regulators tracked here, the first to approve Amoxicillin was the US, on 18 Jan 1974. It is approved in 2 of the 3 regulators tracked here.

USUnited States (FDA)
18 Jan 1974
Amoxil
NDA050459 on Drugs@FDA
First original NDA/BLA approval
EUEuropean Union (EMA)
No centralised EU authorisation (it may be authorised nationally)
First centralised authorisation
CACanada (Health Canada)
13 Oct 1994
Amoxil
Notice of Compliance 5104
First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Amoxicillin

All medicines →
ENNHS England
£11.0m
8,272,046 items dispensed, Aug 2025 to Jul 2026
-22% on the previous 12 months
Net ingredient cost, community prescriptions
USUS Medicaid
$123.2m
11,663,376 prescriptions in 2025 · Amoxicillin, Amoxicillin
-16% on 2024
Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Amoxicillin works

All drug targets →
  • Bacterial penicillin-binding protein inhibitor Inhibitor
    ChEMBL only
Diseases it has been tested for in clinical trials, by furthest phase
  • Acute otitis mediaPhase 3
  • COVID-19Phase 3
  • FeverPhase 3
  • Helicobacter pylori infectious diseasePhase 3
  • Intraventricular hemorrhagePhase 3
  • Low back painPhase 3
  • Parkinson diseasePhase 3
  • SepsisPhase 3
  • TachypneaPhase 3
  • WheezingPhase 3
47 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1082, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3), ligand 10895, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Amoxicillin

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Amoxicillin

ATC code
J01CA04
ChEMBL
CHEMBL1082
DrugBank
DB01060
PubChem CID
40467057
CAS number
26787-78-0
FDA UNII
9EM05410Q9
Wikidata
Q201928
Wikipedia
Amoxicillin

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

What Amoxil is used for

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and other antibacterial drugs, Amoxicillin for Oral Suspension should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin for Oral Suspension is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of the designated bacteria in the conditions listed below: 1.1 Infections of the ear, nose, and throat - due to Streptococcus species.(α- and β-hemolytic isolates only), Streptococcus pneumoniae, Staphylococcus spp., or Haemophilus influen…

Compare Amoxil with

Explore more

How this page is built

The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.

Plain-English summaries and drug-class explainers are written and reviewed by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 4 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.